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A study on interstitial lung disease associated with rheumatoid arthritis 
Dr. Nikhila GS, Dr. S. Veerakesari 
Department of medicine, Coimbatore medical college 
ABSTRACT 
Objective –To describe the clinical features, laboratory profile, radiographic patterns, pulmonary 
function tests abnormalities and broncho-alveolar lavage cytology of patients with RA-ILD, and 
to see if they correlate with each other.  
Methods – Patients with the definite diagnosis of RA attending rheumatology clinic were 
screened clinically for pulmonary signs and symptoms of RA-ILD. All patients with clinical 
suspicion of ILD underwent chest imaging studies including X-ray and HRCT. Those with 
radiological evidence of ILD were included in the study and were subjected to pulmonary 
function test and broncho-alveolar lavage along with other blood investigation. Their clinical, 
radiological and spirometry characteristics were noted and analyzed.  
Results – A total of 30 patients comprising 18 females and 12 males with mean age of 56.2 years 
were included. Mean duration of joint symptom was 7.03 years & pulmonary symptom was 3.16 
years. The average duration of joint symptoms after which the pulmonary symptoms begin to 
manifest was 3.87 years. Dyspnoea was the most common presenting symptom (19 patients or 
63.3%), followed by cough (11 patients or 36.6%). Bibasilar crackles were the most common 
pulmonary sign (28patients or 93.3%). 23 patients (76.7%) had positive RA factor. Reticular 
pattern was the predominant radiological finding in both X-ray (46.7%) and HRCT (53.3%). 
Nine patients (30%) with no evidence of ILD in X-ray had ILD findings in HRCT. Most patients 
(86.6%) showed restrictive abnormality in PFT. Neutrophilic alveolitis was seen in 5 out of ten 
patients who underwent BAL.  
Conclusion - Interstitial lung disease associated with rheumatoid arthritis (RA-ILD) affects men 
and women in their late middle age, and can present within few years of occurrence of joint 
symptoms. HRCT is the most useful test in evaluating suspected patients of RA-ILD compared 
to X-ray. Pulmonary function test is a useful in assessment and follow up of these patients.  
Key words – Rheumatoid arthritis, Interstitial lung disease, HRCT, Pulmonary function test 
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INTRODUCTION 
 
 
Rheumatoid arthritis (RA) is a common systemic disease that manifests 
as inflammatory arthritis of multiple joints and produces a wide variety of extra 
articular manifestations. It affects approximately 1% of adult population1 
worldwide and occurs more commonly in females than in males (2-3:1 ratio).2 
       Due to its systemic nature, RA may result in a variety of extra articular 
manifestations. Previous studies have shown that nearly 50% of patients with 
RA demonstrate some type of extra-articular manifestation involving skin, eye, 
heart and lungs.3,4,29  
      Lung disease is the second most common cause of death in RA5,6. 
Interstitial lung disease (ILD) is one of the important pulmonary manifestations 
of RA like other connective tissue diseases (CTDs). However, ILD associated 
with RA (RA-ILD) differs both histopathologically and prognostically from 
other connective tissue diseases associated ILD (CTD-ILD). Non specific 
interstitial pneumonia (NSIP) pattern predominates in most CTD-ILD whereas 
usual interstitial pneumonia (UIP) pattern is more common in RA and appears 
to predict worse survival.7,8,9 
RA-ILD is associated with significant morbidity and mortality. It can lead 
to progressive fibrosis after variable duration and intensity of disease. The 
diagnostic workup of RA-ILD include chest imaging (X-ray and HRCT), 
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pulmonary function testing (PFT) including diffusion capacity of the lung for 
carbon monoxide (DLCO) and lung biopsy. Bronchoalveolar lavage (BAL) and 
cellular analysis of fluid are useful in excluding the various other causes for 
interstitial pneumonitis.  
The role of these investigations in the diagnostic work up of patients with 
RA-ILD and their correlation between each other and with histopathology is a 
subject of recent interest. There is very little data regarding the different HRCT 
patterns and its correlation with PFT abnormality in Indian population. Hence 
we decided to do this research work to find out the prevalence of X-ray 
abnormality, different HRCT patterns and their correlation with PFT in our 
setting. At present there is no clear consensus regarding the work up of RA 
patients for early detection of ILD, the investigation of choice in RA-ILD and 
its management options. We hope that this study could provide the baseline data 
from which future guidelines regarding the management of RA-ILD in Indian 
patients could evolve.      
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OBJECTIVES OF THE STUDY 
 
 
The study is aimed at  
1. Describing the clinical features, laboratory profile, radiological patterns, 
pulmonary function test (PFT) abnormalities and broncho-alveolar lavage 
(BAL) cytology of patients with rheumatoid arthritis associated 
interstitial lung disease (RA-ILD). 
2. To see if these diagnostic and assessment tools correlate among each 
other and also with the clinical features of the patients.  
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REVIEW OF LITERATURE 
 
 
 Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease. 
The main characteristic is a persistent synovitis of joints, often symmetrical in 
distribution, resulting in pain, stiffness, and loss of function. RA has a wide 
clinical spectrum varying from mild joint symptoms to severe inflammation and 
damage to joints. In addition, being a systemic rather than a localized disease, a 
wide variety of extra-articular features like rheumatoid nodules, vasculitis, 
lymphadenopathy, serositis, and amyloidosis may develop. Our study focuses 
on one such extra articular manifestation namely interstitial lung disease (ILD).  
 
Historical review 
Early descriptions of rheumatoid arthritis in the contemporary medical 
literature can be traced back to the eighteenth century.  Alfred Baring Garrod 
(1859) first used the term “rheumatoid” arthritis.10 In the early days of modern 
medicine, rheumatoid arthritis, like other diseases of unknown causes, was 
thought to result from foci of infection.11,12  
Klemperer et al13 (1942) first proposed that conditions like systemic lupus 
and systemic sclerosis might result from diffuse primary degeneration of 
collagen after considering the fibrinoid changes, thereby giving the name 
collagen vascular diseases to these conditions. Rheumatoid arthritis was then 
added to the group of collagen vascular diseases. Rheumatoid factor was 
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discovered by Waaler et al14 in 1940s in the blood of patients with rheumatoid 
arthritis. It is the first immunological marker of rheumatoid disease to be 
recognized and served to distinguish it from other forms of inflammatory 
arthritis.  
Epidemiology of Rheumatoid arthritis 
Rheumatoid arthritis (RA) is the most common inflammatory arthritis, 
affecting 0.5% to 1% of the general population worldwide. The prevalence of 
RA is nearly constant throughout the world barring some exceptions. It has a 
lower prevalence in some countries like China (0.3%), whereas certain ethnical 
population like pima Indians have a higher prevalence (5%).15 Women are 
affected approximately three times (2-3:1) more often than men. The prevalence 
increases with age, and sex differences diminish in the older age group. 
Etiology 
Although the etiology of RA is unknown, many studies suggest that a 
blend of environmental and genetic factors is responsible; both are necessary, 
but are insufficient alone for full expression of the disease. Genetic factors 
explain the susceptibility for RA in at least 60% of cases.    
Genetics 
Studies conducted on twins have indicated that there is an increased risk 
of disease concordance among monozygotic (MZ) twins. The MZ concordance 
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rate for RA is four times greater than the dizygotic (DZ) twin concordance rate, 
indicating a heritability of 40–60%.16,17  
In the past, genetic studies have focused primarily on the role of the 
major histocompatibility complex (MHC) locus in RA, namely HLADR4 and 
HLADR1.  MHC genes are responsible for about one third of the genetic risk 
for development of RA. Several studies have indicated that these HLA alleles 
are more strongly associated with features of severe disease, such as rheumatoid 
factor positivity, erosions, and nodules.18 In Indian population, HLA DR1 is 
important as a genetic risk factor rather than HLA DR4. The term shared 
epitope (SE) is used to denote the HLA–β1 alleles that convey increased 
susceptibility for RA. It has been noted that person who carries SE allele is at 
increased risk of production of anti-CCP antibodies and also a poor prognosis.   
Recently studies have identified certain non MHC genes involved in the 
genetic predisposition of RA. Some of the promoter regions identified is 
PTPN22, FcRL3, PADI4, CTLA4 and most of these are involved in complex 
immunological signaling pathways.   
Environmental factors 
A number of agents including Epstein Barr virus, parvovirus, proteus, 
cytomegalovirus (CMV), retroviruses, mycoplasma, and mycobacteria have 
been proposed as possible triggers for the development of RA, but there is no 
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conclusive evidence until now. Smoking has been identified as an independent 
risk factor in the development of RA.19 
Pathophysiology 
The pathophysiology of RA is not clearly understood. Triggers like 
infection can initiate an abnormal autoimmune inflammatory response in 
genetically predisposed. The imbalance among the inflammatory mediators 
results in eventual damage to cartilage and bone.20 Synovial inflammation and 
subsequent cascade of reactions leads to proliferation of synovial macrophages, 
fibroblasts, and chondrocytes in the articular cartilage. The enzymes secreted by 
these cells degrade proteoglycans and collagen, causing synovial tissue 
destruction.20  This inflammatory reaction   is accompanied by angiogenesis in 
the synovium, causing irregular regrowth of the synovial tissue forming 
invasive pannus tissue. This stimulates osteoclasts, resulting in further 
inflammation, more cartilage destruction and the characteristic bony erosions.  
Inflammatory mediators along with interleukins, tumor necrosis factor a 
(TNFα), cytokines, and proteinases leads to the development of systemic 
symptoms and the extra-articular manifestations of RA.20,21 It is postulated that 
“shared epitope,” possibly derived from the disease-associated HLA-DR4/1 
allele act as a self antigen and sensitise Tcells.22 Later, these T cells could be 
activated by cross reactive antigens expressing the shared antigen leading to 
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inflammation. It is postulated that multiple infectious agents reactivate RA by 
potentially cross-reactive peptides.22  
Diagnosis of rheumatoid arthritis  
 There is no gold standard investigation available for the diagnosis of 
rheumatoid arthritis. The diagnosis is based on an effective clinical history, 
physical examination, laboratory tests, and exclusion of other diagnoses.  In 
1987, the American College of Rheumatology (ACR), in conjunction with the 
American Rheumatism Association, established 7 diagnostic criteria for clinical 
diagnosis of RA.23 
 When the disease is diagnosed within six months of onset of symptoms, it 
is termed as “Early RA. It has been demonstrated that early treatment has a 
positive impact on disease progression and prognosis. Hence there is 
considerable research being done on this subject.  
 Even at presentation, the treating physician should actively search for 
extra articular involvement as this will influence treatment options and 
determine the disease progression.     
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Criterion Definition# 
Morning stiffness  
 
Morning stiffness in and around the joints, lasting at least 1 hr 
before maximal improvement 
Arthritis of 3 or more 
joint areas 
At least 3 joint areas simultaneously have had soft tissue 
swelling or fluid (not bony overgrowth alone) observed by a 
physician. The 14 possible areas are right or left PIP, MCP, 
wrist, elbow, knee, ankle, and MTP joints 
Arthritis of hand joints 
 
At least 1 area swollen (as defined above) in a wrist, MCP, or 
PIP joint 
Symmetric arthritis Simultaneous involvement of the same joint areas (as defined in 
2) on both sides of the body (bilateral involvement of PIPs, 
MCPs, or MTPs is acceptable without absolute symmetry 
Rheumatoid nodules Subcutaneous nodules, over bony prominences, or extensor 
surfaces, or in juxta-articular regions, observed by a physician 
Serum RF Demonstration of abnormal amounts of serum RF by any 
method for which the result has been positive in <5% of normal 
control subjects 
Radiographic changes Radiographic changes typical of RA on posteroanterior hand and 
wrist radiographs, which must include erosions or unequivocal 
bony decalcification localized in or most marked adjacent to the 
involved joints  
#for classification purposes, a patient shall be said to have RA if he or she has satisfied at least 
4 of these 7 criteria. Criteria 1 through 4 must have been present for at least 6 weeks. Patients 
with 2 clinical diagnoses are not excluded 
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Clinical features 
Onset  
 A slow onset of RA over weeks to months is seen in 55% to 65% of 
cases.24 An acute onset of symptoms that peak within a few days can occur in 8-
15% of patients and an intermediate type of onset, in which symptoms develop 
over days or weeks, occurs in 15% to 20% of patients. The initial symptoms 
may be systemic or articular. The initial presentation can be nonspecific like 
fatigue, malaise, swollen hands, and diffuse musculoskeletal pain with joints 
becoming involved later. Morning stiffness is a cardinal sign that can appear 
even before pain. 
Joint Involvement  
 The joints most commonly involved first in RA are the 
metacarpophalangeal (MCP) joints, proximal interphalangeal (PIP) joints, 
metatarsophalangeal joints, and wrists.25 Larger joints generally are involved 
later. The distal interphalangeal and sacroiliac joints are usually not affected. 
Affected joints are usually warm, tender to palpation, and boggy.  Symmetric 
joint swelling and tenderness on palpation is a characteristic feature of RA joint 
disease. 
 Progressive destruction of joints and soft tissues may lead to chronic 
irreversible deformities and functional impairment.  Cervical spine involvement 
occurs in the form of atlanto-axial subluxation and can lead to compressive 
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myelopathy. Lumbar and thoracic spine is usually not involved. 
Temporomandibular joint can be involved, but functional impairment is rare. 
Extra articular manifestations 
 RA is a systemic disease with a variety of extra articular manifestations. 
The exact prevalence and incidence of extra articular manifestations in RA is 
not known, but it is estimated that as many as 40% of patients may have extra 
articular manifestations, and in ~15% these are severe.  
 Extra articular manifestations may occur during the clinical course, even 
prior to the onset of arthritis. They are the major cause of mortality due to RA26 
with infection as the leading cause of death (25%), followed by cardiac and 
pulmonary disease (18%), with renal and gastrointestinal disease lower in 
frequency (10%). 
Generally, extra articular manifestations occur in individuals with high titers of 
rheumatoid factor or with antibodies to CCP. 
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 Some of the common extra articular manifestations are listed in the 
following table.  
Extra articular manifestations of rheumatoid arthritis 
Rheumatoid nodules of varying size and consistency are found in up to 25% of patients. 
Location: extensor area of the forearm (common), internal organs (rare).  
Complications: gangrene and ulcer formation. 
 
Hematologic: normocytic, normochromic anemia; thrombocytosis or thrombocytopenia; 
lymphadenopathy. 
 
Felty syndrome: the association of RA with leukopenia and splenomegaly 
 
Vasculitis: may involve eyes, brain, skin, renal, cardiovascular, and gastrointestinal (GI) 
tract 
 
Pulmonary: pleural effusions, pulmonary nodules, interstitial lung disease, bronchiolitis 
obliterans with organizing pneumonia; complications of treatment with disease-modifying 
antirheumatic drugs (DMARDs) 
 
Cardiac: pericardial effusions; valvular lesions; cardiac manifestations from systemic 
influences 
of RA such as serositis, amyloidosis, vasculitis, conduction abnormalities secondary to 
nodule 
formation 
 
Renal: microalbuminuria (correlates with disease activity); mesangial glomerulonephritis; 
(nephritic syndrome); nephrotoxicity secondary to DMARDs 
 
Ophthalmologic: keratoconjunctivitis sicca or secondary Sjo’gren syndrome; episcleritis 
and 
scleritis (prompt treatment necessary to avert vision loss); effect of drug therapy—risk of 
retinopathy with hydroxychloroquine requires ongoing surveillance 
Neurologic: mononeuritis multiplex and central nervous system features including 
seizures, aseptic meningitis, and stroke secondary to vasculitis. Entrapment neuropathies 
via nerve 
impingement associated with subluxation of the atlantoaxial joint, amyloid deposits, or 
nodules 
Musculoskeletal: osteoporosis and fractures caused by disease process and corticosteroid 
treatment. Muscular weakness of varying etiology 
Amyloidosis: found in 21% of patients in postmortem studies of patients with RA 
 
Data from Firestein GS, Panayi GS,Wollheim FA. Rheumatoid arthritis: frontiers in 
pathogenesis and treatment. New York: Oxford University Press; 2000. 
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Pulmonary involvement in RA 
Lung is one of the extra articular organs to be affected in RA. In one 
reported series37, lung disease is the second most common cause of death due to 
rheumatoid arthritis second only to cardiac disease.  
In most of the cases joint symptoms of RA precede the onset of 
pulmonary symptoms. In few cases however, lung manifestations may precede 
the onset of joint symptoms, even by several years. This is particularly true for 
Non specific interstitial pneumonia (NSIP),38,39 pleuritis, and occasionally 
obliterative bronchiolitis.  
Pleuropulmonary complications are more likely to occur in patients with 
more severe chronic articular disease, with high titers of rheumatoid factor, and 
in patients who have subcutaneous nodules, as well as other systemic 
complications such as cutaneous vasculitis, myocarditis, pericarditis, ocular 
inflammation, and Felty’s syndrome. 
 Many pulmonary manifestations are directly linked to RA itself and may 
be a result of underlying defects in immunity and chronic inflammation. Some 
are due to exposures and to the treatment of RA with disease-modifying 
antirheumatic drugs (DMARDs). Following is the table showing common 
pleuropulmonary manifestations in RA. 
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Table showing pulmonary manifestations of rheumatoid arthritis 
Lung parenchyma 
Interstitial lung disease (ILD) 
Usual interstitial pneumonitis (UIP) 
Nonspecific interstitial pneumonitis (NSIP) 
Bronchiolitis obliterans with organizing pneumonia (BOOP) 
Lymphocytic interstitial pneumonitis (LIP) 
Desquamative interstitial pneumonitis (DIP) 
Diffuse alveolar damage (DAD) 
Drug-induced pneumonitis 
Rheumatoid nodules (necrobiotic nodules) 
Caplan’s syndrome (silicosis associated with RA) 
Infectious complications 
Airways 
Chronic obstructive pulmonary disease (COPD) 
Bullous emphysema 
Bronchiectasis 
Obliterative bronchiolitis (Constrictive bronchiolitis) 
Pleura 
Pleuritis 
Pleural effusion 
Spontaneous pneumothorax 
Vascular 
Pulmonary hypertension 
Diffuse alveolar hemorrhage 
Extrapulmonary 
Diaphragm weakness 
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Interstitial lung disease 
The interstitial lung diseases are a diverse group of disorders characterized by 
varying degrees of fibrosis and inflammation of the lung parenchyma or 
interstitium. ILD can occur either as a primary condition or secondary to 
multiorgan conditions such as connective tissue diseases (CTDs). It can be 
classified into two groups based on underlying histopathology.27   
I)  Those associated with predominant inflammation and fibrosis 
 Known cause – ex, drug induced, radiation, asbestosis 
 Unknown cause – idiopathic interstitial pneumonias, CTDs 
II)  Those associated with predominant granulomatous reaction 
   Known cause – organic or inorganic dust 
Unknown cause – Sarcoidosis, Wegener’s granulomatosis 
Rheumatoid arthritis associated interstitial lung disease (RA-ILD) 
 Interstitial lung disease is one of the pulmonary manifestations of 
rheumatoid arthritis. The association between ILD and RA was first described 
by Ellman et al in 1948.40 
There are notable differences between ILD occurring in other connective 
tissue disorders and ILD occurring in RA. It is one of the emerging fields of 
research in recent times.  
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Rajasekeran et al55 has compared IPF with RA-ILD and has shown that 
RA-ILD has a better prognosis than IPF. 
Epidemiology of RA-ILD  
RA-ILD has a male preponderance of 3:1. ILD can occur in all CTDs 
whereas the highest prevalence is seen in systemic sclerosis. The lowest 
prevalence is seen in SLE. There is a wide variation in the reported prevalence 
of ILD in RA among various studies from 4% to 68% depending upon the 
diagnostic tool chosen for the study and the population selected for the study 
(asymptomatic, symptomatic) .28,29,30,31 
The two major forms of ILD pattern in RA is Usual interstitial pneumonia 
(UIP) and Non specific interstitial pneumonia (NSIP). UIP carries a uniform 
bad prognosis whereas NSIP is treatable by anti inflammatory treatment. 
Idiopathic UIP is otherwise called as idiopathic pulmonary fibrosis (IPF). 
Risk factors for ILD in RA 
Smoking, male gender and long standing RA are reported as risk factors 
for development of ILD in RA.32,33 Other risk factors proposed for pulmonary 
fibrosis were high titers of rheumatoid factor and the presence of rheumatoid 
nodules. Apart from this, genetic factors (human leukocyte antigen B40 and α1-
antitrypsin) have been described.34,35  Even though a recent study has proposed 
methotrexate therapy as a risk factor for disease progression, the numbers of 
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patients studied were small, and methods of detecting methotrexate toxicity 
were unclear in the study. The role of DMARDs in the pathogenesis or 
progression of ILD among RA patients is uncertain. 
 
Pathogenesis of ILD 
Pathogenesis of pulmonary fibrosis is initiated by microvascular injury, 
which leads to endothelial cell damage and alveolar epithelial injury. This leads 
to activation of the coagulation cascade, release of various cytokines and growth 
factors, and ultimately activation of fibroblasts, a key event in the development 
of fibrosis.  
Clinical features of RA-ILD 
It usually presents as insidious onset of exertional dyspnoea which is the 
commonest symptom. In some patients it may also be subclinical. The reason 
behind dyspnoea is exacerbation of hypoxemia and increased dead space 
ventilation in the early stages and high static recoil of the lung with increased 
work of breathing in the late stage. Most patients also have a non productive 
type of cough. A pleuritic type of chest pain can also occur.41  
Pulmonary hypertension may develop after many years due to advanced 
pulmonary fibrosis leading to right ventricular strain and cor pulmonale. 
Physical examination may show clubbing and evidence of right heart failure in 
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advanced cases. Respiratory system examination shows bibasilar dry crackles in 
most patients with RA-ILD.   
An acute presentation of the disease has been described42 in patients with 
RA-ILD, particularly in patients with UIP pattern.43,44  It is one of the dramatic 
manifestations of RA which takes the form of diffuse alveolar damage or acute 
interstitial pneumonia like picture. The corresponding HRCT finding is the 
presence of diffuse ground glass appearance with or without honeycombing.  
Investigations 
Laboratory tests 
Blood investigations are useful in diagnosis and monitoring of RA in 
general. These investigations do not have a direct role in the evaluation of RA-
ILD. But, as mentioned earlier, high RA titers are associated with severe extra 
articular manifestations.  
Blood investigations include a complete blood cell count with differential 
count, rheumatoid factor (RF), erythrocyte sedimentation rate (ESR) and C-
reactive protein (CRP). Renal and hepatic function parameters are also 
recommended mainly for monitoring drug reactions. 
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Rheumatoid factor (RF) 
IgM isotype is the most frequently measured isotype in RA. Rheumatoid 
factor positivity is seen in 75-80 % of RA patients. Negative result does not 
exclude a diagnosis of RA.  
Incidence of positivity increases with duration of disease and with age. 
Approximately 5% to 10% of healthy individuals are RF positive, and RF 
positivity is found in a number of other diseases also.  
Anticyclic Citrullinated Peptide IgG Antibody (anti-CCP antibody) 
 Anti-CCP antibody is more specific for RA (95 % specificity). It is 
produced at the site of joint inflammation by the B cells, especially during the 
early part of the disease. It can be used in combination with RA factor with 
increased sensitivity. It has got prognostic value also with anti-CCP positivity is 
associated with more severe disease and worse prognosis. 
Radiographic patterns 
X-ray is not a sensitive tool to diagnose ILD in RA. The reported 
prevalence of ILD in RA based on chest x-ray was 1 to 5 %,29 whereas HRCT is 
a highly sensitive diagnostic investigation for RA-ILD, and the reported 
prevalence of interstitial lung disease in early onset RA was 33%.28, 46  
HRCT is the investigation of choice to identify and distinguish between 
UIP and NSIP and invasive investigations such as lung biopsy would be needed 
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only if HRCT is non diagnostic.47, 48 There are four common radiographic 
patterns identified in patients with RA-ILD are,45  
UIP-like pattern   Bilateral subpleural reticulation with or without 
honeycombing 
NSIP-like pattern Predominant ground-glass opacities 
Inflammatory airway disease 
pattern 
Centrilobular branching lines with or without bronchial 
dilatation 
Organizing pneumonia-like pattern Patchy areas of consolidation 
 
Overall, NSIP is the most common type of interstitial lung disease 
pattern, whereas in rheumatoid arthritis, the most common ILD pattern is usual 
interstitial pneumonia (UIP)36, 45 which carries a bad prognosis.  
Pulmonary function tests in RA-ILD 
The most common abnormality noted in PFT is restrictive defect with 
reduced FVC and normal or elevated FEV1/FVC ratio.  
Diffusing lung capacity for carbon monoxide (DLCO) 
In patients with RA-ILD, a reduced diffusing lung capacity for carbon 
monoxide (DLCO) is often the earliest PFT abnormality
49 and DLCO is the most 
sensitive test to diagnose the presence of ILD in RA although it is not specific 
for ILD. A reduced DLCO can also occur if there is emphysema which can 
destroy the vascular beds. Dawson et al44 found that 80% of patients with RA 
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had a reduced DLCO, while only 5–15% of patients had a purely restrictive 
defect on spirometry.  
Broncho alveolar lavage (BAL) 
BAL plays an important role as an investigatory tool to exclude some of 
the differential diagnoses of RA-ILD such as infections, drug reactions, 
malignancy and other co existing disease. 52% of patients with recent onset RA 
showed presence of alveolitis in BAL.28 Patients with clinical interstitial 
pneumonia usually show neutrophilic alveolitis52, 57 whereas approximately one 
third of patients with normal chest x-ray and PFTs revealed lymphocytic 
alveolitis.56  Due to the fact that BAL is not useful in diagnosing RA-ILD it is 
not regularly included in the diagnostic work up of RA-ILD patients. It is done 
whenever there is a necessity to exclude infection or drug related ILD as a cause 
for interstitial pneumonia in RA patients. Bronchoscopy with BAL should be 
considered in the evaluation of new infiltrates in any RA patient receiving 
immunosuppressive therapy.   
Histopathology in RA-ILD 
 Lung biopsy and histopathological examination is the gold standard 
investigation for diagnosis of RA-ILD. Among connective tissue disorders, the 
highest proportion of UIP is found in RA-ILD. Lee et al36 found UIP as the 
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most common histopathologic pattern in RA-ILD patients (56%), followed by 
NSIP (33%) and organizing pneumonia (11%). 
Correlation of histopathology and radiography in RA-ILD 
Studies have demonstrated histopathologic pattern of IPF correlates with 
HRCT findings.47, 50  Similarly, studies to demonstrate the correlation between 
histopathological pattern in RA-ILD and HRCT pattern are available. On the 
whole it has been observed that the presence of reticular shadows in HRCT 
correlates with the presence of UIP pattern in the lung biopsy specimen and the 
presence of ground glass pattern in the HRCT correlates with the presence of 
NSIP in the lung biopsy.36, 45 
Association of pathophysiology to histopathological findings 
Studies that looked into the difference in serological and lymphocyte 
profile between the two radiological patterns could not demonstrate a significant 
difference. Gochuico et al51 demonstrated that patients BAL fluid of patients 
with UIP pattern in HRCT contained increased concentration of platelet derived 
growth factor AB, gamma-interferon and transforming growth factor-β. Lee et 
al36 and Biederer et al52 have showed that smoking habit was more prevalent 
among patients who showed UIP pattern in their HRCT.  
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Treatment of ILD in RA 
 There is no well controlled, randomized trial on the treatment of RA-ILD. 
Immunosuppressive therapy is the mainstay of treatment available for patients 
with progressive pulmonary disease. Supportive therapy with home oxygen and 
respiratory rehabilitation offers some help.  
Lung transplantation is the final option available for those without 
significant involvement of other organ systems.  
In asymptomatic patients with HRCT evidence of ILD, whether treatment 
offers substantial benefit is not yet clear. In symptomatic patients, studies have 
reported positive response to treatment with corticosterioids, azathioprine, 
cyclosporine and cyclophosphamide.57,58 
Rapidly progressive disease and disease with extensive lung involvement 
usually needs treatment with either daily oral or monthly cyclophosphamide in 
combination with corticosteroids.58 
Mild yet progressive disease is usually treated with azathioprine together 
with prednisolone. If toxicity is noted in the absence of expected response to 
treatment, then consideration should be given to stop treatment.58  All patients 
with ILD should receive prophylaxis against pneumocystis jeroveci. A recent 
study has reported beneficial effects with mycophenolate mofetil.59,60 
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In patients whose lung disease has already progressed to extensive 
fibrosis, the therapeutic options are very limited. They usually show little 
response to immunosuppressive therapy, instead suffer from drug related 
toxicity. Hence, lung transplantation may be the only hope in these patients. 
Drugs such as Rituzumab and TNFα inhibitors have not undergone 
rigorous trial for their usage in RA-ILD. Some studies have reported worsening 
of pulmonary status in patients taking TNFα inhibitors due to their pulmonary 
toxicity.61,62,63 
UIP Vs NSIP : Response to treatment 
It is not known whether there exists a difference in response to treatment 
between the two predominant histopathologic patterns – UIP and NSIP. The 
conclusion of a recent narrative review is that UIP responds poorly to treatment 
with corticosteroids.54  But there is a need for further prospective studies to look 
upon the response to treatment among the different ILD patterns.   
Treatment related toxicity  
Treatment related lung injury can be caused by a number of therapeutic 
agents.  Gold and penicillamine can induce diffuse alveolar damage, 
osteoporosis and bronchiolitis obliterans.68,69 Methotrexate itself can induce 
varying patterns of interstitial pneumonia. RA patients treated with 
methotrexate can develop life threatening acute pneumonitis. Usual clinical 
features are dry cough or dyspnoea.  The usual HRCT pattern observed in this 
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condition is patchy ground glass opacities with centrilobular nodules and 
lymphadenopathy. One useful investigation in this setting is BAL which usually 
shows lymphocytosis. Histology reveals interstitial fibrosis or pneumonia, small 
and ill defined granulomas and increased tissue eosinophils.70  Methotrexate 
induced interstitial pneumonitis is mainly a diagnosis of exclusion, hence it is 
very important to rule out opportunistic infection or exacerbations of pre-
existing interstitial pneumonia. Once diagnosed, treatment options are drug 
withdrawal and high dose corticosteroid therapy. The reported mortality in a 
recent study is 15%, hence close monitoring and early diagnostic measures such 
as BAL or lung biopsy are recommended during methotrexate treatment. A 
guideline for methotrexate therapy has been proposed recently.71 
Prognosis of RA-ILD 
As for as asymptomatic PFT abnormality is concerned, the clinical course 
of the disease was found to be stable without any increase in the PFT 
abnormality over a time period of ten years according to a longitudinal study.64  
The disease can take either of two courses like a fulminant one or one 
with a slow progression. There is a wide variation in the reported two year 
mortality of RA-ILD patients ranging from 14% to 50%.43,44 According to one 
study done on hospitalized patients with RA-ILD, the median survival was 3.5 
years and the 5 year mortality rate was 50%.65 When compared with idiopathic 
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pulmonary fibrosis (IPF), certain studies have reported a similar mortality rate,66 
whereas others have reported a higher survival among patients with RA-ILD.58   
Prognostic significance – UIP Vs NSIP 
When compared with NSIP pattern, there are many prognostic difference 
of significance in UIP pattern. Patients with UIP pattern in HRCT have 
heightened risk of progression, and are associated with bad prognosis and 
increased mortality.53  
Approach to ILD in RA67 
In a recent review (Eunice et al)67 of the RA-ILD, authors have proposed the 
following clinical approach to patients with rheumatoid arthritis, with reference 
to ILD –  
• All patients with RA should undergo annual screening for ILD that includes 
clinical history and examination to look for pulmonary signs and symptoms.  
• X-ray – to be taken at the time of diagnosis of RA, and then alternate years 
thereafter. In long standing cases, annual chest x-ray is advised.  
• When ILD is suspected, exclude alternative etiologies like ILD secondary to 
occupational and environmental exposures, medications, or the presence of 
concomitant secondary Sjogren syndrome. Serologic evaluation for the 
presence of auto antibodies (anti-SS-A/Ro and anti-SSB/ La) should be 
performed. 
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• Patients with suspected RA- ILD should undergo spirometry and diffusing 
capacity of the lung for carbon monoxide. 
• HRCT scans are advocated in all patients suspected to have ILD. It has a 
high sensitivity for detecting RA-ILD and can predict the possible 
histopathological pattern and indirectly, the prognosis. Lung biopsy may be 
considered when HRCT is inconsistent. 
• NSIP pattern needs aggressive treatment with pharmacologic therapy.  
• UIP pattern indicates worse prognosis in which the ultimate option would be 
lung transplantation. Further research is needed on the role of pharmacologic 
therapy in this situation.  
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MATERIALS AND METHODS 
 
Place of study 
 The study was conducted at Coimbatore medical college hospital 
during the period of September 2010 to August 2011.  
Type of the study 
It is a cross sectional study. 
Study population 
The study population consisted of consecutive patients with a definite 
diagnosis of RA (based on American rheumatism association criteria 1987) 
attending Rheumatology OPD, Coimbatore medical college hospital during the 
study period, with features suggestive of ILD (Pulmonary symptoms and signs) 
together with either or both of the following- 
1. Suspicious interstitial attenuation pattern in chest x-ray. 
2. ILD pattern in HRCT. 
Inclusion criteria 
1. Definite diagnosis of RA (ACR criteria 1987). 
2. Pulmonary signs and symptoms together with radiological features 
consistent with ILD. 
3. Age > 18 years. 
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Exclusion criteria 
1. RA patients without pulmonary signs or symptoms. 
2. Other connective tissue disorders. 
3. Age < 18 years. 
4. Pregnant and lactating women. 
5. Sick patients unable to undergo PFT. 
6. Pulmonary symptoms due to other chronic respiratory illnesses like 
infection, allergic alveolitis, pneumoconiosis etc.., 
Methodology 
The Coimbatore medical college hospital runs a rheumatology clinic 
every day. The subjects for this study were chosen from this clinic. Approval to 
conduct the study is obtained from the institute’s ethical committee. All patients 
are included to the study only after obtaining informed consent from them.   
Patients with the definite diagnosis of RA were initially screened 
clinically for pulmonary signs and symptoms of RA-ILD. All patients with 
clinical suspicion of ILD underwent chest imaging studies including X-ray and 
HRCT. Those with radiological evidence of ILD were included in the study as 
study subjects. All of the patients included in the study were receiving drug 
treatment according to the standard protocol.    
A detailed history was taken using the standard proforma prepared for 
the study purpose. Proforma included collection of personal data, smoking 
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habits, duration of joint symptoms and pulmonary symptoms, previous 
respiratory illnesses if any, other addictions etc. The presence of pulmonary 
symptoms like cough with or without expectoration, dyspnoea, wheeze, chest 
pain and hemoptysis are noted. General symptoms like weight loss, fatigue, 
fever, anorexia were also noted. Then a detailed physical examination was 
carried out that include documentation of pallor, cyanosis, clubbing, pedal 
edema, respiratory signs including bibasilar crackles, tachypnea, rhonchi, 
features of heart failure etc.  
Blood investigations were done in the patients, which includes complete 
hemogram, urine routine analysis, ESR, C – reactive protein and rheumatoid 
factor.  
Radiological investigation 
Patients were then subjected to radiological imaging (chest x-ray and 
HRCT). Chest x-ray patterns were described as normal, nodular, 
honeycombing, ground-glass and reticular patterns. HRCT was performed with 
1mm thick sections at 10mm intervals. Reports were analyzed by two 
radiologists blinded to the study and the consensus report was taken as final. 
Patterns were described as pure reticular, pure ground-glass, mixed pattern, 
normal or other pattern such as emphysema, bronchiectasis, and consolidation. 
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Description of CT findings 
• Reticular pattern – presence of intercepting lines with appearance varying 
from a fine network to frank honeycombing 
• Ground-glass pattern – patchy or diffuse increase in lung density that did not 
obscure pulmonary vasculature 
• Mixed – where ground-glass and reticulation are of equal proportions 
The predominant lobe involved was also described.  
Pulmonary function test was done within two weeks of HRCT scan. All 
patients underwent PFT according to the standard protocol and included 
spirometry and lung volumes. Measurements were expressed as percentage of 
value predicted for age, gender and height according to standardized tables. PFT 
patterns were classified as restrictive (mild / moderate / severe) abnormality, 
obstructive abnormality, mixed defect and normal pattern as described below -   
Normal   - FVC >80%, FEV1/FVC - 70 To80% 
Mild restriction - FVC 60 TO 80%, FEV1/FVC >80% 
Moderate  - FVC 50 To 60%, FEV1/FVC >80% 
Severe  - FVC <50%, FEV1/FVC >80% 
Obstructive  - FVC >60%, FEV1/FVC < 70% 
Mixed  - FVC < 60%, FEV1/FVC < 70% 
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Broncho-alveolar lavage was done in 10 patients. In others, it was not 
done because 15 patients declined the procedure; five patients were excluded 
due to advanced disease and poor respiratory reserve. Cytological analysis was 
done for differential count and results were expressed as neutrophilic / 
lymphocytic alveolitis. Differential count was considered normal if values are as 
follows –  
Non smokers: lymphocytes < 15%,  neutrophils < 2%,  eosinophils < 0.5% 
Smokers: lymphocytes <10%, neutrophils < 4%, eosinophils < 1% 
Statistical analysis 
Analysis was done using Sofastat software. Continuous data were 
described as mean and standard deviation (mean +/- SD), and categorical 
variables as numbers. Comparisons between two categories were made using 2 
tailed student t-test for continuous variables. To analyze categorical data, chi 
square test is performed. Pearson correlation is used to correlate the continuous 
variables like disease duration, HRCT patterns and pulmonary function test 
abnormalities.  
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RESULTS 
 
 
During the study period, a total of 30 patients were included in the study, 
of age ranging from 36 years to 72 years. 
Age distribution 
The mean age of patients with RA-ILD included in our study was 56.2 
years (range = 36 to 72 years). The most common age group affected in our 
study population was 61 to 70 years (14 patients or 46.7%), followed by age 
group of 51 to 60 years (7 patients or 23.3%). There was only 1 patient above 
the age group of 70 years constituting 3.3% of the total number of patients.  
• Mean age of male patients = 59.1 years & female patients = 54.2 years 
Table 1 – Age wise distribution of study population (n=30) 
Age group (years) Number of patients Percentage 
31 to 40 3 10 
41 to 50 5 16.7 
51 to 60 7 23.3 
61 to 70 14 46.7 
Above 70 1 3.3 
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Chart 1 – Age wise distribution of study population 
 
 
 
X axis – age group; Y axis – number of patients and percentage 
Table 2 - Age group wise distribution of male and female patients 
 
Age group (years) Male patients (%) Female patients (%) 
31 to 40 0 3 (16.7) 
41 to 50 2 (16.7) 3 (16.7) 
51 to 60 3 (25) 4 (22.2) 
61 to 70 6 (50) 8 (44.4) 
Above 70 1 (8.3) 0 
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Chart 2 – age group wise distribution of gender 
 
 
X axis = age group; Y axis = number of patients 
Gender frequency 
In our study, 60% of the study subjects (18 patients) were females and 40% of 
the population was male subjects (12 patients). 
Chart 3 – Gender frequency 
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Smoking 
11 out of 12 male subjects were smokers (36.7% of the total subjects).  
None of the female patients were smokers. 
Joint symptoms and pulmonary symptoms  
Among the study population, the mean duration of joint symptom was 
7.03 years, and mean duration of pulmonary symptom was 3.16 years. Two 
patients (6.7%) had joint symptoms for less than 3 years, nine patients (30%) 
had joint symptoms for 3 to 6 years, ten patients (33.3%) had joint symptoms 
for 6 to 9 years and nine patients (30%) had symptoms over and above 9 years.  
 
Table 3 – Duration of joint symptoms in patients 
 
Duration of joint symptoms Number of patients Percentage (%) 
Less than 3 years 2 6.7 
3 to 6 years 9 30 
6 to 9 years 10 33.3 
More than 9 years 9 30 
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The average duration of joint symptoms after which the pulmonary 
symptoms begin to manifest was 3.87 years. There was considerable variation 
in the duration of pulmonary symptom ranging from one to five years. In all but 
one patient, joint manifestation preceded pulmonary complaints. 
 
 
On an average, pulmonary symptoms developed after 3.87 years of joint 
symptoms in the study group.  
Chart 4 - Relationship between occurrence of joint and pulmonary 
symptoms in the study population 
 
 
X axis = individual patients; Y axis = number of years 
 
 
PULMONARY  
SYMPTOMS 
3.87 years 
 
JOINT  
SYMPTOMS  
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Frequency of pulmonary symptoms and general symptoms 
In all patients, the symptom of cough appeared at some point of time 
during the course of their illness (100%), whereas dyspnoea was present in 27 
patients (90%). When the presenting pulmonary symptom was analyzed, 
dyspnoea outnumbered cough as the predominant presenting pulmonary feature. 
Dyspnoea was the presenting complaint in 19 out of 30 patients (63.3 %) and 
cough was the presenting complaint in 11 out of 30 patients (36.6%). Chest pain 
was observed in eight of the thirty patients (26.6%) during the course of their 
illnesses.  Apart from this, other general symptoms noted were fatigue, weight 
loss and fever as shown in the table.  
Table 4 – Frequency of Pulmonary and general symptoms (n=30) 
 
Symptoms Number of patients Percentage 
Cough 
Dyspnoea 
Chest pain 
Fatigue 
Weight loss 
Fever 
30 
27 
8 
23 
16 
3 
100% 
90% 
26.6% 
76.6% 
53.3% 
10% 
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Chart 5 - Frequency of pulmonary and general symptoms 
 
 
X axis = number of patients 
 
Respiratory signs 
         Among the physical examination findings, presence of bibasilar crackles 
was the most common finding (28 patients, 93.3%). Tachypnoea was present in 
16 patients (53.3%) and rhonchi in 9 patients (30%). Clubbing was seen in 10 
patients (33.3%)  
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Table 5 – Physical examination findings (n=30) 
 
Respiratory sign Number of patients Percentage (%) 
Bibasilar crackles 28 93.3 
Tachypnoea 16 53.3 
Rhonchi 9 30 
Clubbing 10 33.3 
 
Blood investigations 
o Anemia was found in 23 patients (76.7%).  
o An elevated ESR of more than 30 at one hour was found in 27 patients 
(90%), whereas 16 patients had ESR more than 60.  
o CRP was positive in 24 patients (80%).  
o Rheumatoid factor was positive in 23 patients (76.7%) of the total subjects.  
 
Table 6 - Laboratory findings (n=30) 
 
Investigation Number of patients Percentage 
Anemia 
ESR > 30 
ESR > 60 
Positive CRP 
Positive RA factor 
23 
27 
16 
24 
23 
76.7% 
90% 
53.3% 
80% 
76.7% 
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Radiography 
X-ray appearance  
In our study, six patients (20%) had normal x-ray appearance. Fourteen 
(46.7%) patients showed reticular pattern which was the most common x-ray 
appearance. One patient had honeycombing appearance in x-ray (3.3%). Six 
patients (20%) had nodular opacities. Three patients (10%) had findings such as 
bronchiectasis and pleural thickening. None of the patients had pleural effusion. 
Thereby, nine out of thirty patients (30%) showed x-ray appearance inconsistent 
with ILD.  
Table 7 – X-ray appearance (n=30) 
 
X-ray pattern Number of patients Percentage 
Reticular 14 46.7 
Honeycombing 1 3.3 
Nodular 6 20 
Others 3 10 
Normal 6 20 
Total 30 100 
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Chart 6 showing x-ray appearances in 30 patients 
 
 
HRCT pattern 
In our study, all patients showed features suggestive of ILD in HRCT. 
Three different patterns were identified such as pure reticular, pure ground-glass 
and mixed pattern. Sixteen patients (53.3%) showed reticular pattern, five 
patients (16.7%) showed ground-glass pattern and nine patients (30%) showed 
mixed pattern. Thereby, reticular pattern was the predominant HRCT pattern 
followed by mixed pattern. Honeycombing appearance was seen in five 
patients. As it represents late stage of reticular pattern, it was counted along 
with reticular pattern. Four patients showed bronchiectactic changes along with 
other ILD findings. Bilateral lower lobe was the most common lobes to be 
involved (28 patients out of 30, 93.3%)    
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Table 8 - showing frequency of HRCT pattern 
 
HRCT pattern Number of patients Percentage 
Reticular 16 53.3 
Ground-glass 5 16.7 
Mixed 9 30 
Total 30 100 
 
Chart 7 showing HRCT patterns found in the study 
 
 
 
Pulmonary function test 
All patients underwent pulmonary function test within two weeks of 
HRCT as part of our protocol. Most of the patients (26 out 30, 86.6%) showed 
restrictive pattern in PFT. Two patients showed obstructive pattern (6.7%) in 
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PFT and the remaining two (6.7%) showed mixed defect in PFT. Among the 
patients with restrictive abnormality in PFT, seventeen patients (56.7%) had 
severe restriction. Seven patients (23.3%) had moderate degree of restriction in 
PFT. Two patients (6.7%) had mild restriction. 
Table-9 showing pulmonary function abnormality in the study population 
 
PFT abnormality Number of patients Percentage 
Severe restriction 17 56.7 
Moderate restriction 7 23.3 
Mild restriction 2 6.7 
Obstructive 2 6.7 
Mixed 2 6.7 
Total 30 100 
 
Chart 8 - showing pulmonary function test abnormality (PFT) 
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Broncho-alveolar lavage (BAL) 
Five out of ten patients (50%) in whom BAL was done, showed 
neutrophilic alveolitis. Two (20%) showed lymphocytic alveolitis. Three 
patients (30%) had their BAL pattern within normal limits. Four out of five 
patients with ground-glass pattern (80%) showed neutrophilic alveolitis in BAL.  
Smoking Vs HRCT 
Out of the 11 smokers, none had a ground-glass pattern in HRCT, five 
persons had reticular pattern and six persons had mixed pattern.  
Table 10 showing relation of smoking history to HRCT 
 
 Smoking 
HRCT 
 Yes No 
Reticular 5 11 
Ground-glass 0 5 
Mixed 6 3 
Total 11 19 
p- value = 0.037   
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Chart 9 showing relation between smoking habit and HRCT pattern 
 
Relationship between pulmonary symptom duration and HRCT pattern 
For patients who showed predominant reticular pattern in HRCT, the 
average duration of pulmonary symptoms was 4.19 years, as compared to 
patients with predominant ground glass pattern in HRCT, for whom the average 
duration of pulmonary symptoms was 1.2 years. The difference between the 
mean duration of symptoms between the two populations (reticular pattern in 
HRCT Vs ground-glass pattern in HRCT) was statistically significant as shown 
in the following table 11.  
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Table 11 – Duration of pulmonary symptoms and HRCT pattern 
HRCT pattern Duration of pulmonary symptoms 
Predominant reticular pattern 4.19 years* 
Predominant ground-glass pattern 1.2 years* 
P value – 0.0001; Confidence interval = 2.22 to 3.75 (95%) 
 
Chart 10 - showing that ground-glass pattern is an earlier HRCT finding 
compared with reticular which in most cases a late finding 
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HRCT pattern and pulmonary function test 
Among the three different patterns of HRCT findings in our study 
subjects, reticular pattern was more commonly associated with severe 
restriction in pulmonary function test, and was statistically significant.  
 
Table 12- showing relation between HRCT pattern and PFT findings 
 
 
HRCT 
Reticular Mixed Ground-glass Total 
obs exp obs exp obs exp obs exp 
PFT 
Mild 0 1.1 0 0.6 2 0.3 2 2 
Mod 1 3.7 5 2.1 1 1.2 7 7 
Severe 15 9.1 2 5.1 0 2.8 17 17 
mixed 0 1.1 0 0.6 2 0.3 2 2 
obstructive 0 1.1 2 0.6 0 0.3 2 2 
total 16 16 9 9 5 5 30 30 
 
p value: < 0.001 
Pearson's Chi Square statistic: 39.297 
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Chart 11 - showing relation between HRCT finding and PFT abnormality 
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The mean FVC% among patients showing pure reticular pattern in 
HRCT was 20.18, whereas it was 51.4 in patients with pure ground-glass 
pattern. This finding was statistically significant.  
Table 13 - FVC comparison between pure reticular and pure ground-glass 
Group Number Mean FVC% SD Min FVC Max FVC 
Reticular 16 20.188 10.055 13 56 
Ground-glass 5 51.4 10.383 40 65.0 
p-value < 0.001 
Chart 12 showing FVC to HRCT association 
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Chart 13 - Correlation between duration of pulmonary symptom & 
FEV1/FVC ratio 
 
Two-tailed p value: 0.046 
Pearson's R statistic: 0.367 
Slope: 3.432 
Inference = There was a linear correlation between duration of pulmonary symptom and 
FEV1/FVC ratio  
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Chart 14 - Correlation between duration of pulmonary  
symptom & FVC % 
 
Two-tailed p value: < 0.001 
Pearson's R statistic: -0.647 
Slope: -9.813 
Inference = There was a negative correlation between duration of pulmonary symptom & 
FVC % 
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X-ray versus HRCT 
When the agreement between X-ray and HRCT was tested, it was not 
statistically significant, even though most of the patients with x-ray finding of 
reticular pattern had a similar pattern in HRCT. 
 
Table 14 - X-ray versus HRCT 
 HRCT 
Mixed Ground – Glass Reticular 
Obs Exp Obs Exp Obs Exp 
X-ray 
Honeycomb 0 0.3 0 0.2 1 0.5 
Nodular 2 1.8 1 1.0 3 3.2 
Others 2 0.9 1 0.5 0 1.6 
Reticular  3 4.2 0 2.3 11 7.5 
Normal 2 1.8 3 1.0 1 3.2 
Total 9 9 5 5 16 16 
p-value = 0.076  
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Chart 15 - X-ray versus HRCT 
 
 
 
Other results 
We tested the associations between the following variables but found to be 
statistically not significant.  
• Rheumatoid factor and HRCT finding; p value = 0.312 
• Age versus FEV1/FVC; p-value = 0.845 
• Age versus FVC%; p-value = 0.182 
• Joint symptom duration versus HRCT; p-value=0.156 
• Smoking versus PFT; p-value=0.207 
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SUMMARY OF RESULTS 
• A total of 30 patients comprising 18 females and 12 males with mean age of 
56.2 years were included.  
• Mean duration of joint symptom was 7.03 years & pulmonary symptom was 
3.16 years. The average duration of joint symptoms after which the 
pulmonary symptoms begin to manifest was 3.87 years.  
• Dyspnoea was the most common presenting symptom (19 patients or 
63.3%), followed by cough (11 patients or 36.6%).  
• Bibasilar crackles were the most common pulmonary sign (28patients or 
93.3%).  
• RA factor was positive in 23 patients (76.6%)  
• Reticular pattern was the predominant radiological finding in both X-ray 
(46.7%) and HRCT (53.3%).  
• Nine patients (30%) with no evidence of ILD in X-ray had ILD findings in 
HRCT. Most patients (86.6%) showed restrictive abnormality in PFT.  
• Neutrophilic alveolitis was seen in 5 out of ten patients who underwent 
BAL.  
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DISCUSSION 
Indian study on RA-ILD81 
There is very little Indian literature on ILD in RA. In a study done at 
Baroda, authors have concluded that 36% of RA have ILD. HRCT was more 
sensitive than X-ray and spirometry in diagnosing ILD in RA.  
Average age and duration of illness 
In our study, we have included patients of RA-ILD ranging from 36 to 72 
years. Among the study subjects, the most common age group was between 61 
to 70 years. Studies20 that have looked into the extra articular manifestations of 
RA, have reported that these are common between 50 to 60 years.  In studies 
focusing on RA-ILD, the most common age group reported to be affected by 
RA-ILD is around 60 years44, 62, 63  
Table 15 – Average age & duration of illness compared with other studies 
Study Average age in years Average disease course (months) 
Biederer et al44 61 123 
Muller – Leisse et al62 61 144 
Remy-Jardin et al63 57 144 
Hakala et al65 64 180 
Our study* 56.2 84 
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The common age group affected by RA-ILD, in our population is similar 
to the one reported elsewhere (see table). In our study, female patients had an 
earlier onset (54.2years) when compared to male patients (59.1 years).  
Several studies have reported longstanding RA as a risk factor for ILD28,30. In 
our study, the mean duration of joint symptom was 7.02 years and 63.3% of the 
study population had more than 6 years of joint symptoms. 
Gender distribution 
Even though, most of previously done studies show male predominance 
of RA-ILD72, 73, there are few studies such as Tanaka et al in 200445 showing 
female predominance like our study.  
ILD as the presenting manifestation 
Previous studies have reported that joint symptoms precede pulmonary 
symptoms in majority of the patients with RA-ILD74. However Lee HK et al.36 
in their study have found out that they can occur simultaneously or pulmonary 
symptoms can occur earlier than joint symptoms, especially in NSIP pattern. 
Similar results were reported in studies done by Fujita J, et al.38 and Sato T, et 
al39.   
Even though, in our study, only one patient (3.3 %) presented with 
pulmonary symptom, previous studies have reported that up to 20% of patients 
with RA can have pulmonary symptom as the initial presentation75, hence forth 
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we advocate considering underlying CTDs as a possible cause in all ILD 
patients.  
ILD – an early extra articular manifestation of RA 
Our study has shown that on an average, pulmonary symptoms developed 
3.87 years after joint symptoms. This suggests that ILD can be a relatively 
early extra articular manifestation of RA. We advocate active surveillance 
for development of ILD in all patients with RA. In a study by Gabbay et al done 
on recent onset RA patients (<2years), 58% had ILD28, detected during the 
study, thereby reinforcing the above recommendation.  
Most commons 
 The most common respiratory symptom in our study was cough (100%). 
The most common presenting symptom was dyspnoea. The most common 
general symptom was fatigue. The most common respiratory sign was bibasilar 
fine crackles. These findings were consistent with the literature76.  
Clubbing was present in one third of the patients (10 out of 30 patients, 
33.3%). Similar to our finding, it has been noticed in the past that, in 
comparison with idiopathic pulmonary fibrosis, clubbing is less common in RA-
ILD55. 
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Lab parameters 
Prevalence of RA factor in the study group was 76.7% comparable with 
the estimated prevalence. Acute phase reactants were elevated in more than 
80% of patients. Anemia was noted in three fourth of the patients. 
Role of radiological investigations in RA-ILD 
It is a known fact that X-ray is an insensitive tool to diagnose RA-
ILD76,77. In our study too, we have noticed that in nine patients (30%), X-ray 
missed a diagnosis of ILD which was picked up by HRCT. 
HRCT is highly sensitive for detecting the presence of ILD and it is 
abnormal in up to 80% of clinically suspected RA-ILD.78   
HRCT characteristics of the study population 
a. The predominant HRCT pattern was reticular (53.3%).  
b. Ground-glass pattern was seen in 16.7%. 
c. The most common lobe involved was bilateral lower lobe.  
d. Reticular pattern was associated with longer duration of illness, 
whereas ground-glass opacity was seen in patients with shorter 
duration illness. 
e. Bronchial abnormalities like bronchiectasis were present in 13.3%  
f. Nodular opacity and honeycombing were seen in 16.7% each 
In the literature available until now, reticular pattern with or without 
honeycombing is a major abnormality and is more common than ground-glass 
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opacity.30,32,43,52 Also, it has been previously noted that ground-glass pattern is 
common during early part of the disease.28,52 
Previous studies have shown that reticular pattern in HRCT is 
irreversible77 and corresponds to UIP pattern in histopathology (HP) and 
ground-glass pattern in HRCT corresponds to NSIP pattern.36,45 UIP pattern in 
HP has a uniformly bad prognosis, whereas NSIP has good prognosis. So, in our 
study, there is a considerable population of patients (46.7%) with either pure 
ground-glass or mixed pattern in HRCT, representing a potentially treatable 
population. The remaining 53.3% of patients with pure reticular pattern may 
respond poorly to immunosuppressive therapy54 and may need lung 
transplantation ultimately which is farfetched in our setup.  
Smoking Vs HRCT 
 There were 11smokers in our study, in whom six showed reticular pattern 
and five showed mixed pattern, none had ground-glass pattern which carries 
good prognosis. Ground-glass pattern was seen only in non smokers. The 
association was statistically significant. It is a significant finding that smokers 
have a high chance of harboring ILD with poor prognostic features 
(reticular).    
Pulmonary function test (PFT) 
As expected, most of our patients had restrictive abnormality in PFT 
(86.7%). This has been previously reported in studies by Dawson JK, et al30 and 
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Banks J, et al.79 Also there was positive correlation between duration of 
pulmonary symptoms with FEV1/FVC ratio and negative correlation of 
pulmonary symptom duration with FVC% indicating that ILD worsens with 
advancing years.  
A novel finding in our study is that most patients with severe restriction 
in PFT had reticular HRCT pattern, the two patients with mild restriction in PFT 
had ground-glass pattern in HRCT and most patients with moderate restriction 
of lung function in PFT had mixed pattern in HRCT. At a glance, it looks like 
PFT abnormalities are directly linked to HRCT patterns. Possible explanation 
would be that, most patients with ground-glass appearance in HRCT had shorter 
duration of illness and thereby lesser degree of extent of disease and hence 
producing a milder PFT abnormality as compared to patients with reticular 
pattern in whom the disease existed for longer duration. We recommend serial 
CT and PFTs to establish a relation between these two.   
Broncho-alveolar lavage (BAL) 
As part of our study, we did BAL in 10 patients. Fifteen patients declined 
the procedure and five patients were excluded due to advanced disease. Fifty 
percent of total patients in whom BLA was done and eighty percent of the 
patients with ground-glass appearance in HRCT showed neutrophilic alveolitis 
in BAL, in par with other studies.52,56,57 
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CONCLUSION 
 
1. Interstitial lung disease associated with rheumatoid arthritis (RA-ILD) 
affects men and women in their late middle age. 
2. RA-ILD can present within few years of occurrence of  joint symptoms. 
3. The treating physician should actively look for development of 
respiratory signs and symptoms in a patient with rheumatoid arthritis. 
4. HRCT is the most useful test in evaluating suspected patients of RA-ILD 
as X-ray alone in an insensitive tool. 
5. Reticular pattern is the most common HRCT finding in RA-ILD which 
indicates advanced disease. 
6. Ground-glass appearance in HRCT signifies early disease and warrants 
aggressive treatment as it is potentially reversible.  
7. Pulmonary function test is a useful tool in assessing the severity of RA-
ILD and complements HRCT in diagnosis and management of RA-ILD. 
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SUMMARY 
 
Objective –  
 
1. To describe the clinical features, laboratory profile, radiographic patterns, 
pulmonary function tests abnormalities and broncho-alveolar lavage 
cytology of patients with RA-ILD. 
2. To find out whether these investigations correlate with each other.  
Methodology –  
• Patients with the definite diagnosis of RA attending rheumatology 
clinic were screened clinically for pulmonary signs and symptoms of 
RA-ILD.  
• All patients with clinical suspicion of ILD underwent chest imaging 
studies including X-ray and HRCT.  
• Those with radiological evidence of ILD formed the study population. 
They were subjected to pulmonary function test and broncho-alveolar 
lavage along with other blood investigation. Their clinical, 
radiological and spirometry characteristics were noted and analyzed.  
Results –  
• A total of 30 patients comprising 18 females and 12 males with mean 
age of 56.2 years were included.  
• Mean duration of joint symptom was 7.03 years & pulmonary 
symptom was 3.16 years. The average duration of joint symptoms 
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after which the pulmonary symptoms begin to manifest was 3.87 
years.  
• Dyspnoea was the most common presenting symptom (19 patients or 
63.3%), followed by cough (11 patients or 36.6%).  
• Bibasilar crackles were the most common pulmonary sign (28patients 
or 93.3%).  
• 23 patients (76.7%) had positive RA factor.  
• Reticular pattern was the predominant radiological finding in both X-
ray (46.7%) and HRCT (53.3%).  
• Nine patients (30%) with no evidence of ILD in X-ray had ILD 
findings in HRCT.  
• Most patients (86.6%) showed restrictive abnormality in PFT.  
• Neutrophilic alveolitis was seen in 5 out of ten patients who 
underwent BAL.  
Conclusion –  
• Interstitial lung disease associated with rheumatoid arthritis (RA-ILD) 
affects men and women in their late middle age, and can present 
within few years of occurrence of joint symptoms.  
• HRCT is the most useful test in evaluating suspected patients of RA-
ILD compared to X-ray. Pulmonary function test is useful in 
assessment and follow up of these patients. 
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PROFORMA 
 
Name      Age/sex   Occupation 
Residence        OP/IP no -   
Smoker – Yes / No 
Duration – joint symptoms ____yrs pulmonary symptoms ____yrs 
Presenting respiratory symptom – cough / dyspnoea / wheeze / chest pain / hemoptysis  
Other respiratory symptoms - cough / dyspnoea / wheeze / chest pain / hemoptysis 
General symptoms – weight loss / fatigue / fever / others  
Physical examination – pallor / cyanosis / clubbing / pedal edema / others  
Pulse = _____ / min BP = ______ mmHg RR = _____ / min  
RS examination – tachypnoea / rhonchi / crackles / consolidation / pleural effusion / others 
CVS examination – ↑JVP / loud P2 / cardiac murmur / pericardial rub  
_____________________________________________________________ 
 
Lab results – CBC = Hb –     gm/dL;  TC –        DC –   platelet –   
                      ESR –    CRP –    RA factor –   
           Blood urea –   S.creatinine –   RBS –   S.Br –  
           SGOT –   SGPT –   S. ALP –  
           Urine routine – 
Imaging studies –  
CXR = normal / reticular / nodular / honeycombing / others 
HRCT = normal / pure reticular / pure ground-glass / mixed 
Pulmonary function test =   
 FEV1 / FVC =  
 FVC % =  
 Pattern = restriction (mild / moderate / severe) / obstruction / mixed  
Bronchoalveolar lavage = normal / lymphocytic / neutrophilic   
Notes   _______________________________________________________ 
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 sym no sym  = 0 
Cough  = 1 
 Dyspnea = 2 
Hemoptysis = 3 
Chestpain = 4 
 
oms no sym  = 0 
Fatigue   = 1 
 Wt loss  = 2 
 Fever   = 3 
  tachypnea = 1 
 Crackles = 2 
 Rhonchi = 3 
 Cyanosis = 4 
 Clubbing = 5 
 Others = 6 
ved RUL  = 1 
 RML  = 2 
 RLL  = 3 
 LUL  = 4 
 LLG  = 5 
 LLL  = 6 
